Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Wojewodka, Gabriella ^a   De Sanctis, Juan B ^b   Bernier, Joanie ^c   Bérubé, Julie ^d   Ahlgren, Heather G ^a   Gruber, Jim ^c   Landry, Jennifer ^c   Lands, Larry C ^e   Nguyen, Dao ^a   Rousseau, Simon ^a   Benedetti, Andrea ^a,c   Matouk, Elias ^c   Radzioch, Danuta ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c MCGILL UNIVERSITY   (Canada)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARACHIDONIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; POLYUNSATURATED FATTY ACID; TUMOR NECROSIS FACTOR; VASCULOTROPIN; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNSATURATED FATTY ACID; VASCULOTROPIN A;

ADULT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID PEROXIDATION; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PROBABILITY; PROSPECTIVE STUDY; PULMONARY EXACERBATION; QUALITY OF LIFE; SPIROMETRY; ADOLESCENT; BLOOD; COMPLICATION; DISEASE COURSE; INFLAMMATION; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; INFLAMMATION; INTERLEUKINS; KAPLAN-MEIER ESTIMATE; LIPID PEROXIDATION; LONGITUDINAL STUDIES; LUNG DISEASES; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SPIROMETRY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84895765518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088567     Document Type: Article

References (54)

1. Parkins MD, Rendall JC, Elborn JS (2012) Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 141: 485-493.
2. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, et al. (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182: 627-632.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, et al. (2001) Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153: 345-352. (Pubitemid 32144560)
4. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, et al. (2012) Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 40: 61-66.
5. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, et al. (2011) Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 66: 680-685.
6. Hakimi Shoki A, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS (2013) Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. Chest epub Jul 18.
7. Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, et al. (2013) Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial. Contemp Clin Trials 36: 460-469.
8. Hoek RA, Paats MS, Pas SD, Bakker M, Hoogsteden HC, et al. (2013) Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients. Scand J Infect Dis 45: 65-69.
9. Etherington C, Naseer R, Conway SP, Whitaker P, Denton M, et al. (2013) The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J Cyst Fibros epub Jul 23.
10. Farhat SC, Almeida MB, Silva-Filho LV, Farhat J, Rodrigues JC, et al. (2013) Ozone is associated with an increased risk of respiratory exacerbations in patients with cystic fibrosis. Chest 144: 1186-1192.
11. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, et al. (2012) The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 7: e45001.
12. Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, et al. (2013) A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol 48: 954-961.
13. Sutton S, Rosenbluth D, Raghavan D, Zheng J, Jain R (2013) Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men. Pediatr Pulmonol epub Mar 4.
14. Sequeiros IM, Jarad N (2012) Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis 9: 9-16.
15. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, et al. (2010) Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 9: 193-198.
16. Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K (1997) Internal consistency reliability and predictive validity of a modified N. Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J 10: 2004-2013. (Pubitemid 27406432)
17. Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K (1999) Construct and longitudinal validity of a modified Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J 13: 552-559. (Pubitemid 29180164)
18. Society AT (1987) Standardization of Spirometry, a Statement of the American Thoracic Society. Am Rev Respir Dis 136: 1285-1298.
19. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725-734. (Pubitemid 13101554)
20. Quittner AL, Sweeny S, Watrous M, Munzenberger P, Bearss K, et al. (2000) Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 25: 403-414.
21. Folch J, Lees M, Sloane Stanely GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
22. Schlenk H, Gellerman J (1960) Esterification of fatty acids with diazomethane on a small scale. Anal Chem 32: 1412-1414.
23. Oborna I, Wojewodka G, De Sanctis JB, Fingerova H, Svobodova M, et al. (2010) Increased lipid peroxidation and abnormal fatty acid profiles in seminal and blood plasma of normozoospermic males from infertile couples. Hum Reprod 25: 308-316.
24. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, et al. (2004) Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 350: 560-569. (Pubitemid 38160786)
25. Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, et al. (2009) Cystic Fibrosis Fatty Acid Imbalance is Linked to Ceramide Deficiency and Corrected by Fenretinide. Am J Respir Cell Mol Biol 41: 100-106.
26. Gilljam H, Strandvik B, Ellin A, Wiman LG (1986) Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand J Clin Lab Invest 46: 511-518. (Pubitemid 17173235)
27. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, et al. (2013) Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 68: 532-539.
28. Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS (2007) The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 42: 729-735. (Pubitemid 47242871)
29. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ (1998) Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 157: 1764-1769.
30. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, et al. (2012) Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS One 7: e42748.
31. Chiron R, Grumbach YY, Quynh NV, Verriere V, Urbach V (2008) Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy. J Cyst Fibros 7: 463-468.
32. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, et al. (2005) Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 40: 15-21. (Pubitemid 40917903)
33. Lloyd-Still JD, Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, et al. (2006) Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22: 36-46. (Pubitemid 43175783)
34. Strandvik B, Bronnegard M, Gilljam H, Carlstedt-Duke J (1988) Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis. ScandJGastroenterolSuppl 143: 1-4.
35. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB (1993) Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. AmRevRespirDis 148: 896-901. (Pubitemid 23301203)
36. Lucidi V, Ciabattoni G, Bella S, Barnes PJ, Montuschi P (2008) Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. Free RadicBiolMed 45: 913-919.
37. Lawrence RH, Sorrell TC (1994) Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis. Clin Exp Immunol 98: 12-16. (Pubitemid 24315444)
38. Weldon SM, Mullen AC, Loscher CE, Hurley LA, Roche HM (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18: 250-258. (Pubitemid 46389578)
39. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, et al. (2008) Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. AmJRespirCell MolBiol 38: 47-56.
40. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr., et al. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. AmJRespirCrit Care Med 176: 957-969. (Pubitemid 350127838)
41. Szaff M, Hoiby N, Flensborg EW (1983) Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 72: 651-657. (Pubitemid 13048784)
42. Nir M, Lanng S, Johansen HK, Koch C (1996) Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre. Thorax 51: 1023-1027. (Pubitemid 26360179)
43. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, et al. (2000) Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 55: 355-358. (Pubitemid 30245690)
44. Breen L, Aswani N (2012) Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 7: CD002767.
45. Finkelstein SM, Wielinski CL, Kujawa SJ, Loewenson R, Warwick WJ (1992) The impact of home monitoring and daily diary recording on patient status in cystic fibrosis. Pediatr Pulmonol 12: 3-10.
46. Sequeiros IM, Jarad NA (2012) Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis 9: 213-220.
47. McColley SA, Stellmach V, Boas SR, Jain M, Crawford SE (2000) Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 161: 1877-1880. (Pubitemid 30418123)
48. Durieu I, Abbas-Chorfa F, Drai J, Iwaz J, Steghens JP, et al. (2007) Plasma fatty acids and lipid hydroperoxides increase after antibiotic therapy in cystic fibrosis. Eur Respir J 29: 958-964. (Pubitemid 46711901)
49. Durieu I, Vericel E, Guichardant D, Roth H, Steghens JP, et al. (2007) Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study. J Cyst Fibros 6: 320-326. (Pubitemid 47324149)
50. McGrath LT, Mallon P, Dowey L, Silke B, McClean E, et al. (1999) Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 54: 518-523. (Pubitemid 29241624)
51. Cantin A, Woods DE (1993) Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest 91: 38-45. (Pubitemid 23037250)
52. Gziut M, MacGregor HJ, Nevell TG, Mason T, Laight D, et al. (2013) Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity. Br J Pharmacol 168: 1165-1181.
53. Halliwell B, Chirico S (1993) Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 57: 715S-724S.
54. Mutoh A, Ueda S (2013) Peroxidized unsaturated fatty acids stimulate Toll-like receptor 4 signaling in endothelial cells. Life Sci 92: 984-992.